FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washii

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ngton, D.C. 20549		
-------------------	--	--

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							000()				mpany 7 tot								
1. Name and Address of Reporting Person* PARSHALL B LYNNE						2. Issuer Name and Ticker or Trading Symbol CYTOKINETICS INC [CYTK]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
					٦				30 11 10		,	:	X Directo	or		10% Ow	ner		
(Last) (First) (Middle) 280 EAST GRAND AVENUE					Date o		t Trar	nsaction (M	onth/	/Day/Year)		Officer below)	(give title		Other (s below)	pecify			
(Street) SOUTH SAN FRANCISCO CA 94080				4. II	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																
		Tab	le I - Nor	-Deriv	vative	e Se	curitie	s A	cquired,	Dis	posed o	f, or Bei	neficial	ly Owned	ı ,				
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)					Execution Date,			Code (Instr. 5)					5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	ion(s)			(Instr. 4)	
		7	Γable II -								osed of, convertil			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day/	Date,	4. Transa Code (I 8)				6. Date Exercisa Expiration Date (Month/Day/Year		Amount of		f g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares						
Non- Qualified Stock Option (right to buy)	\$8.75	01/02/2018			A		5,714		02/02/201	3 ⁽¹⁾	01/02/2028	Common Stock	5,714	\$3.5002 ⁽²⁾	5,714		D		

Explanation of Responses:

- 1. This option shall vest and become exercisable as to 5,714 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019.
- 2. This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of \$40,000.00

By: Peter S. Roddy For: B. 01/03/2018 Lynne Parshall

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.